Analysts and Calls -- UBS | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Analysts and Calls -- UBS

An SI Board Since October 2002

Posts	SubjectMarks	Bans
19	2	0

Emcee: Icebrg	Type: Unmoderated

Introduction Compact

A good opportunity to start up a thread for UBS. 8 USD for Sepracor seems very conservative.

RESEARCH ALERT-UBS cuts Sepracor price target
Wednesday October 23, 12:01 pm ET

NEW YORK, Oct 23 (Reuters) - UBS Warburg on Wednesday said it cut its price target on drug company Sepracor Inc. (NasdaqNM:SEPR - News) to $8 from $12, after the company reported a quarterly loss and said that the timing for the clinical trials on all of its pipeline products had been pushed back.

UBS said it now expects the company to report a loss of $1.67 per share in 2003, not a loss of $1.20 per share, due to higher research and development costs related to the trials.

It lowered its 2004 earnings estimate to 30 cents per share from 50 cents per share and 2005 earnings estimate to $1.50 per share from $2.50 per share to reflect later product launches.

It has a "hold" rating on the stock.

Sepracor shares were trading up 1.9 percent, or 13 cents, at $7.43 in morning Nasdaq trade. That's far from its year high on Dec. 28, 2001, of $60.05

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
19	Conflict Issue Over Analyst's Deal By LANDON THOMAS Jr. [NYT] April 8, 200	Icebrg	-	4/8/2003
18	(off topic) I was at a recent dinner, where there were a couple of investment b	scaram(o)uche	-	2/5/2003
17	Posted for the name of another analyst on the team: >>NEW YORK, Feb 5 (Re	tuck	-	2/5/2003
16	Feuerstein has a half-assed second piece out today. (IMO, he reads every single	scaram(o)uche	-	12/9/2002
15	Needham does not agreee with UBS. From today's Business Week Online - >	Findit	-	12/9/2002
14	UBS. Seems a most appropriate acronym now, in reference to Gitkin. Cheers, Tu	tuck	-	12/7/2002
13	dunno. sure would like to know, and it certainly wouldn't be surprising if	scaram(o)uche	-	12/6/2002
12	So where do you think Gitkin got his ideas? I can't really see him travellin	Icebrg	-	12/6/2002
11	Oh, yeah, fully agreed. I didn't mean to hold him up as a stellar example.	scaram(o)uche	-	12/6/2002
10	>>Gitkin could be right on the ball, for all we know.>> I am not di	Icebrg	-	12/6/2002
9	>> (Interesting site btw.) << Cool!!! Thanks. >> wonder if	scaram(o)uche	-	12/6/2002
8	I wonder if Gitkin was using the Risk Brothers as undercover agents? Or if he wa	Icebrg	-	12/6/2002
7	last three questions on the conference call come from Fulcrum.	scaram(o)uche	-	12/6/2002
6	"An absolute fabrication." Crooke	scaram(o)uche	-	12/6/2002
5	"There has been no analysis of this trial." Crooke	scaram(o)uche	-	12/6/2002
4	Isis Pharmaceuticals Statement Regarding UBS Warburg Report Friday December 6, 4	Icebrg	-	12/6/2002
3	<i>One clinical oncologist familiar with the Affinitac test results told T	scaram(o)uche	-	12/6/2002
2	Isis Pharmaceuticals (ISIS:Nasdaq - news - commentary - research - analysis) qu	Icebrg	-	12/6/2002
1	SEPR looks like an excellent short, thanks for the headsup	Wayne Rumball	-	10/24/2002

Go to reply# or date (mm/dd/yy):